CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue that stimulates the pituitary pathway for growth-hormone release. It is often discussed alongside ipamorelin because the two act through complementary mechanisms.

Research perspective: Much of the published human pharmacology relates to the longer-acting DAC version (see below). Evidence that CJC-1295 improves muscle growth, fat loss or recovery in healthy adults remains limited.

Ipamorelin is a selective ghrelin-receptor agonist studied for stimulating pulsatile growth-hormone release. Its selectivity is a major reason it remains of interest in peptide research.

Research perspective: Research on CJC-1295 and ipamorelin separately supports their effects on GH signaling; the popular combination itself has much less controlled human outcome data than either mechanism is sometimes assumed to have.

Tesamorelin is a synthetic GHRH analogue with an established medical use in reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It stimulates the body’s own growth-hormone pathway, which is why it is relevant to research on body composition.

Research perspective: The evidence is strongest for visceral fat in its approved indication. Benefits for muscle development or athletic performance in healthy adults have not been established.

CJC-1295 with DAC is a longer-acting GHRH analogue designed to extend exposure compared with shorter-acting formulations. In controlled human research, single injections produced dose-dependent increases in growth hormone and IGF-1, with effects persisting for days.

Published study protocol: Early human pharmacology studies evaluated single doses in the approximately 30–60 µg/kg range among other dose levels. This describes a research protocol, not a dosing recommendation, and benefits such as improved muscle development, sleep or recovery in healthy individuals remain insufficiently established. Research ↗

TB-500 is a name used for products associated with thymosin beta-4, a naturally occurring protein involved in cell migration, actin regulation and wound-healing biology. Research has explored its potential role in tissue repair, angiogenesis and recovery.

Research perspective: Commercial TB-500 should not automatically be treated as identical to every thymosin beta-4 preparation studied in the scientific literature; formulation and study model matter, and evidence for muscle recovery, tendon healing or athletic performance remains limited.

Delta sleep-inducing peptide (DSIP) is a short peptide originally investigated for its possible relationship with sleep regulation. Research has explored its influence on sleep patterns, neuroendocrine activity and stress-related responses, which links it to recovery science because sleep is central to physical recovery.

Research perspective: Findings have been inconsistent, and its effectiveness as a treatment for insomnia or as a means of improving restorative sleep has not been firmly established.